Asia-pacific Chronic Idiopathic Constipation Drug Market Forecast 2017-2025
KEY FINDINGS The Asia-Pacific chronic idiopathic constipation drug market is predicted to expand at a CAGR of 10.30% over the forecast period of 2017-2025. The revenue generated by the market is expected to rise from $683 million in 2016 and reach $1615 million by 2025.
MARKET INSIGHTS The Asian CIC drug market can be segmented by the type of drug and by the type of prescription. The drug lubiprostone is dominating the drug segment closely followed by the drug linaclotide. By prescription type, over the counter drugs are more popular as they can be obtained without a doctor’s prescription. The major driver increasing the growth of the Asian market is the modern dietary habits such as intake of foods rich in animal fats especially dairy products, eggs and meat or foods that have refined sugar and low fiber. Although the market looks promising for the coming years, factors like alternate surgical treatments and the lack of awareness about such drugs in the masses are acting as restraints for market growth.
COMPETITIVE INSIGHTS Ferring International Center S.A, Progenics Pharmaceuticals Inc Chugai Pharmaceutical, Theravance Biopharma Inc, Allergens, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, GlaxoSmithKline, Pfizer, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Roche Holding Ag ,Merck Sharp & Dohme, Bayer Ag, and Sucampo Pharmaceuticals Inc, are some of the leading companies in the market.